Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Fluorouracil Adjuvant in En-DCR for Small Lacrimal Sac PANDO
NCT07154121Recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of fluorouracil in Primary acquired nasolacrimal duct obstruction (PANDO) (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Surgical success rate at 6 months. Started Sep 2025; status: recruiting.
02
Drugs
fluorouracil
03
Conditions
Primary acquired nasolacrimal duct obstruction (PANDO)
Beyond the preview
Go deeper on NCT07154121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154121.